Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Buffalo. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in Buffalo at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
Sponsor: Indaptus Therapeutics, Inc
Check if you qualify for this advanced solid tumors clinical trial in Buffalo, NY
If you're searching for advanced solid tumors treatment options in Buffalo, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Buffalo research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.